Share This Link

Maintain bedrest when taking this medication: Oxycodone is an opioid analgesic that can cause sedation and dizziness, but bedrest is not required. Encouraging normal activity as tolerated helps prevent complications like deconditioning and constipation.

An increased respiratory rate is expected: Oxycodone typically depresses respiratory function rather than increasing respiratory rate. Monitoring for signs of respiratory depression is important, especially in older adults or those with comorbidities.

Take with meals to minimize diarrhea: Opioids like oxycodone often cause constipation rather than diarrhea. Taking with food may help minimize nausea, but diarrhea is not an expected side effect.

Hypersensitivity to the drug: A history of hypersensitivity is a contraindication for GLP-1 ago-nists rather than an indication. Administering the drug to someone with an allergy could trigger se-vere allergic reactions, including anaphylaxis.

Gastroparesis: GLP-1 agonists can slow gastric emptying, which may worsen gastroparesis symp-toms. Therefore, gastroparesis is a precaution, not an indication, for using this class of medications.

Medullary thyroid carcinoma: A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 is a contraindication for GLP-1 agonists due to potential in-creased risk of thyroid tumors.

Administer flumazenil: Flumazenil reverses benzodiazepines, not opioids. Giving it in an opioid overdose would provide no therapeutic benefit and could complicate care by masking overlapping sedative effects from unknown co ingested substances.

Encourage ambulation: Clients with opioid overdose often have depressed consciousness, poor respiratory effort, and impaired safety awareness. Ambulation increases the risk of falls, injury, and worsened hypoxia, making it unsafe during the acute phase.

Request a sedative: Sedating a client who already has CNS and respiratory depression from opi-oids can further suppress breathing and worsen hypoventilation. This would significantly increase the risk of respiratory failure.

The client experienced drug toxicity: Drug toxicity usually results from excessive dosing or ac-cumulation, causing systemic effects. Hives alone are not indicative of toxicity but rather an im-mune-mediated reaction.

The drug produced a therapeutic effect: Therapeutic effects are the desired outcomes of a medi-cation, such as symptom relief or disease control. Hives are an unwanted effect and do not indicate that the medication is achieving its intended purpose.

The drug has not reached a steady state: Steady state refers to the point at which drug intake and elimination are balanced. Hives are unrelated to steady-state pharmacokinetics and occur independ-ent of plasma concentration.

The client is crying when talking to the nurse: Crying is an observable behavior and constitutes objective data because it can be seen and measured by the nurse.

The client has a healing wound on their foot: The presence and appearance of a wound are ob-servable and measurable, making this objective data rather than subjective.

The client’s blood glucose level is 98 mg/dL: Laboratory values are objective data because they provide quantifiable measurements obtained through testing and do not rely on the client’s report.

Inhibits development of female sex hormones: Methimazole does not have any effect on estro-gen, progesterone, or other female sex hormones. Its pharmacologic action is specific to thyroid hormone synthesis and does not influence reproductive hormone pathways.

Replaces endogenous thyroid hormones: Thyroid hormone replacement therapy, such as levo-thyroxine, is designed to supplement or replace deficient thyroid hormones in hypothyroidism. Me-thimazole does not replace hormones but instead decreases their production in hyperthyroid states.

Promotes development of female sex hormones: Methimazole does not stimulate or promote the production of any sex hormones. Its mechanism is limited to inhibiting thyroid hormone synthesis, and it has no role in reproductive hormone regulation.

"This drug should make me feel full.": Pioglitazone is a thiazolidinedione used to improve insu-lin sensitivity in type 2 diabetes. It does not act as an appetite suppressant, so expecting a feeling of fullness reflects a misunderstanding of its mechanism.

"This drug may cause flatulence.": While some medications for diabetes, such as alpha-glucosidase inhibitors, can cause flatulence, pioglitazone does not commonly produce this side ef-fect. Expecting gas is not accurate for this drug.

"This drug may cause weight loss.": Pioglitazone is more commonly associated with weight gain due to fluid retention rather than weight loss. Believing it promotes weight loss indicates a miscon-ception about the drug’s effects.